The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs

@inproceedings{Meibohm2006TheRO,
  title={The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs},
  author={Bernd Meibohm},
  year={2006}
}

Figures from this paper

Integrating cell-level kinetic modeling into the optimization of cancer therapeutics

A detailed mechanistic model of the targeted cellular system that explicitly takes into account receptor binding and trafficking inside the cell is presented and that is used to derive reduced models of drug degradation which retain a mechanistic interpretation.

Safety and efficacy of interleukin inhibitors in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis

The reviewed findings suggest that the interleukin inhibitors approved and currently in use in clinical practice for the treatment of rheumatoid arthritis, psoriasis, and psoriatic arthritis can be considered a safe and efficient option for these diseases in elderly patients.

Challenges in the Pharmacokinetics of Therapeutic Proteins

Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed‐Effects Modeling

It is shown that a pharmacokinetic (PK) similarity analysis can be performed using nonlinear mixed‐effects models (NLMEM) because NCA is an easier approach because it does not require data modeling; however, NLMEM leads to a better understanding of the underlying biological system.

Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.

This review article will focus on the current use of mass spectrometry for the study of the metabolism of peptide and protein drugs.

Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling

A systematic approach to integrate cell-level kinetic models and pharmacokinetic compartment models for the development of therapeutic antibodies indicates that observed differences in the therapeutic effects of high affinity antibodies in the market and in clinical development may result mainly from Fc-mediated indirect mechanisms such as antibody-dependent cell cytotoxicity.

Analysis of pharmacokinetic similarity of biologics using nonlinear mixed effects modelling

This work used two studies comparing different biosimilars: a three-way crossover trial on somatropin and a parallel group trial on epoetin alpha, to show that a pharmacokinetic (PK) similarity analysis can be performed with nonlinear mixed effects models (NLMEM).

References

SHOWING 1-10 OF 19 REFERENCES

Pharmacokinetic/Pharmacodynamic Modeling in Drug Development

Pharmacokinetic (PK) and pharmacodynamic (PD) modeling is employed to establish correlation of the concentration-time relationship (PK) with effect-concentration relationship (PD) in order to provide

Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans

Two international meetings were convened in 1998 to review the current science of drug development and the potential opportunities to optimize the evaluation of new drugs in humans and the relative merits of various strategies intended to accelerate the clinical development of drugs.

Population modelling in drug development

Throughout this paper, prediction and advocate mechanistic as opposed to empirical modelling are emphasized, and it is argued that the Bayesian approach is particularly natural in this setting.

Kinetics of pharmacologic response.

Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development

In the past decade considerable progress has been made in the field of integrated pharmacokineticpharmacodynamic modelling, as can be deduced from the considerable increase in the number of papers on

Pharmacokinetic/pharmacodynamic studies in drug product development.

Rigorous implementation of the PK/PD concepts in drug product development provides a rationale, scientifically based framework for efficient decision making regarding the selection of potential drug candidates, for maximum information gain from the performed experiments and studies, and for conducting fewer, more focused clinical trials with improved efficiency and cost effectiveness.

Monoclonal antibodies.

A regulatory perspective on pharmacokinetic/pharmacodynamic modelling

We present an integrated summary from statistical and pharmacological perspectives of pharmacokinetic/pharmacodynamic (PK/PD) modelling and its use in drug development and regulation for guiding

Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development

This report derives from the conference on “The Integration of Pharmacokinetic, Pharmacodynamic and Toxicokinetic Principles in Rational Drug Development,” held on April 24–26, 1991 in Arlington, VA.

Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

The expanded use of PK/PD-modelling is assumed to be highly beneficial for drug development as well as applied pharmacotherapy and will most likely improve the current state of applied therapeutics.